Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures.

The aim of this review was to summarize previously published classifications for ovarian hyperstimulation syndrome (OHSS), as well as to analyse the available methods for preventing OHSS. Withholding hCG and cycle cancellation--once the main methods of preventing OHSS--are now seldom used. There is a growing body of evidence to support the use of coasting to prevent OHSS, without cycle cancellation. However, most studies on coasting are retrospective, and well-designed prospective randomized studies are lacking. There is no current consensus as to how coasting should be carried out. A serum estradiol level of 3000 pg/ml is generally considered optimum for administration of hCG. It appears that intravenous albumin or hydroxyethyl starch at the time of oocyte retrieval is beneficial in preventing OHSS, but does not offer complete protection. There is insufficient evidence to support routine cryopreservation of all embryos for the later transfer of frozen-thawed embryos in high-risk patients. Several uncontrolled studies have reported the protective effect of GnRH agonist to trigger ovulation in preventing OHSS, though the method is applicable solely for gonadotrophin-only or GnRH antagonist cycles. A single dose of recombinant LH to trigger ovulation significantly reduced OHSS as compared with hCG. The possible role of GnRH antagonist protocols in reducing the incidence of OHSS is debatable. The above measures to prevent OHSS were successful in reducing the incidence of the syndrome, but complete prevention is not as yet possible.

[1]  U. Waldenström,et al.  High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: a multicentre study. , 1999, Human reproduction.

[2]  Z. Rosenwaks,et al.  Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.

[3]  C. Tay.  Use of gonadotrophin-releasing hormone agonists to trigger ovulation , 2002, Human fertility.

[4]  Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. , 2001, The Journal of clinical endocrinology and metabolism.

[5]  L. O’Dea,et al.  Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer. , 2001, Fertility and sterility.

[6]  R. Shaw,et al.  The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. , 1997, Human reproduction.

[7]  S. Fishel,et al.  Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin? , 1997, Fertility and sterility.

[8]  Z. Ben-Rafael,et al.  A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin. , 1995, Fertility and sterility.

[9]  D. Serr,et al.  Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment. , 1967, American journal of obstetrics and gynecology.

[10]  Serge Rozenberg,et al.  Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). , 2003, Human reproduction update.

[11]  E. Alexopoulou,et al.  Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. , 2002, Fertility and sterility.

[12]  M. Aboulghar,et al.  Modern management of ovarian hyperstimulation syndrome. , 1991, Human Reproduction.

[13]  Y. Beyth,et al.  The significance of 17β-estradiol levels in highly responding women during ovulation induction in IVF treatment: Its impact and prognostic value with respect to oocyte maturation and treatment outcome , 1993, Journal of Assisted Reproduction and Genetics.

[14]  Y. S. Yang,et al.  Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.

[15]  E. Shalev,et al.  Induction of pre-ovulatory luteinizing hormone surge by gonadotrophin-releasing hormone agonist for women at risk for developing the ovarian hyperstimulation syndrome. , 1994, Human reproduction.

[16]  M. Aboulghar,et al.  Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. , 2000, The Cochrane database of systematic reviews.

[17]  M. Aboulghar,et al.  GnRH antagonist in assisted reproduction: a Cochrane review. , 2002, Human reproduction.

[18]  J. Grudzinskas,et al.  'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome. , 2002, Human reproduction.

[19]  R. Casper,et al.  Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. , 1992, Fertility and sterility.

[20]  A. Katalinic,et al.  Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol , 2001, Archives of Gynecology and Obstetrics.

[21]  M. Brunner,et al.  Endocrinology: Prediction of ovarian hyperstimulation syndrome of baseline ovarian volume prior to stimulation , 1996 .

[22]  M. J. Berger,et al.  The use of gonadotropins for the induction of ovulation in women with polycystic ovarian disease. , 1977, Fertility and sterility.

[23]  A. Zosmer,et al.  Value of measuring serum FSH in addition to serum estradiol in a coasting programme to prevent severe OHSS. , 2002, Human reproduction.

[24]  S. Yen,et al.  Hormonal dynamics at midcycle: a reevaluation. , 1983, The Journal of clinical endocrinology and metabolism.

[25]  G. Burford,et al.  A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization. , 1988, Fertility and sterility.

[26]  G. Serour,et al.  Follicular aspiration does not protect against the development of ovarian hyperstimulation syndrome , 1992, Journal of Assisted Reproduction and Genetics.

[27]  N. Simberg,et al.  The effect of cryopreservation in prevention of ovarian hyperstimulation syndrome , 1995, British journal of obstetrics and gynaecology.

[28]  A. Lanzone,et al.  The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. , 1997, The Journal of clinical endocrinology and metabolism.

[29]  P. De Sutter,et al.  The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. , 1993, Human reproduction.

[30]  D. C. Knight,et al.  A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. , 2000, Human reproduction.

[31]  J. Schenker,et al.  Ovarian Hyperstimulation Syndrome: A Current Survey , 1978 .

[32]  S. Stone,et al.  CLINICAL REPORT: The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome , 1993 .

[33]  J. Gerris,et al.  Endocrinology: Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome , 1993 .

[34]  J. Smitz,et al.  Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. , 1992, Human reproduction.

[35]  P. Leung,et al.  Relationship of gonadotropin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. , 1986, American journal of obstetrics and gynecology.

[36]  D. de Ziegler,et al.  Effects of gonadotropin-releasing hormone (GnRH) agonist on pituitary and ovarian responses to pulsatile GnRH therapy in polycystic ovarian disease. , 1990, Fertility and Sterility.

[37]  V. Insler,et al.  Ovulation induction in perspective. , 2002, Human reproduction update.

[38]  J. Skurnick,et al.  "Coasting" does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. , 1998, Fertility and sterility.

[39]  J. Balmaceda,et al.  Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction , 1994, Journal of Assisted Reproduction and Genetics.

[40]  G. Borm,et al.  Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. , 2000, Human reproduction.

[41]  J. Maltau,et al.  [In vitro fertilization]. , 1988, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[42]  W. Kuczyński,et al.  Correctly timed coasting reduces the risk of ovarian hyperstimulation syndrome and gives good cycle outcome in an in vitro fertilization program , 2001, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[43]  J. Balasch,et al.  Triggering of ovulation by a gonadotropin releasing hormone agonist in gonadotropin-stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy. , 1994, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[44]  G. Serour,et al.  Management of Severe Ovarian Hyperstimulation Syndrome by Ascitic Fluid Aspiration and Intensive Intravenous Fluid Therapy , 1993, Obstetrics and gynecology.

[45]  T. Tanbo,et al.  In-vitro fertilization in infertile women with the polycystic ovarian syndrome. , 1991, Human reproduction.

[46]  M. Haupt,et al.  Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. , 1983, Critical care medicine.

[47]  E. Shalev,et al.  The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. , 2002, Human reproduction.

[48]  M. Feinman,et al.  'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. , 1995, Human reproduction.

[49]  T. European Middle East Orgalutran Study Group*.  Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. , 2001, Human reproduction.

[50]  R. Kudo,et al.  Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. , 2002, Human reproduction.

[51]  S. Shapiro,et al.  Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. , 1983, Fertility and sterility.

[52]  S. Stone,et al.  Successful pregnancy outcome after cryopreservation of all fresh embryos with subsequent transfer into an unstimulated cycle. , 1995, Fertility and sterility.

[53]  M. Nueckel,et al.  Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme. , 1997, Human reproduction.

[54]  B. Erstad,et al.  The use of albumin in clinical practice. , 1991, Archives of internal medicine.

[55]  L. Gianaroli,et al.  Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. , 1999, Human reproduction.

[56]  R. Frydman,et al.  Severe ovarian hyperstimulation syndrome using agonists of gonadotropin‐releasing hormone for in vitro fertilization: A European series and a proposal for prevention , 1991, Fertility and sterility.

[57]  S. Stone,et al.  Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. , 1991, Human reproduction.

[58]  J. Nisker,et al.  Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome? , 1998, Human reproduction.

[59]  P. Devroey,et al.  Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. , 2000, Human reproduction.

[60]  R. Frydman,et al.  Selective oocyte retrieval: a new approach to ovarian hyperstimulation. , 1988, Fertility and sterility.

[61]  J. Llach,et al.  Severe ovarian hyperstimulation syndrome: Role of peripheral vasodilation , 1991, Fertility and sterility.

[62]  T. Tomaževič,et al.  Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome , 1996, Journal of Assisted Reproduction and Genetics.

[63]  M. Sütterlin,et al.  Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. , 1998, Human reproduction.

[64]  P. Devroey,et al.  Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide®) in controlled ovarian stimulation for assisted reproduction , 2000, Archives of Gynecology and Obstetrics.

[65]  R. Homburg,et al.  Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. , 1999, Human reproduction update.

[66]  Tom Searle,et al.  The value of routine estradiol monitoring in assisted conception cycles , 2002, Acta obstetricia et gynecologica Scandinavica.

[67]  Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG. , 2001, Fertility and sterility.

[68]  J. Tullis.  Albumin. 1. Background and use. , 1977, JAMA.

[69]  J. Antoine,et al.  Comparison between long and short protocols of LHRH agonist in the treatment of polycystic ovary disease by in-vitro fertilization. , 1988, Human reproduction.

[70]  C. Friedman,et al.  Severe ovarian hyperstimulation following follicular aspiration. , 1984, American journal of obstetrics and gynecology.

[71]  N. Dean,et al.  Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. , 1996, Fertility and sterility.

[72]  S. Stone,et al.  The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. , 1993, Human reproduction.

[73]  E. Loumaye,et al.  Relationship of baseline ovarian volume to ovarian response in World Health Organization II anovulatory patients who underwent ovulation induction with gonadotropins. , 2002, Fertility and sterility.

[74]  S. L. Tan,et al.  A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. , 1993, Human reproduction.

[75]  R. Frydman,et al.  Une alternative à la réduction embryonnaire: la réduction folliculaire , 1984 .

[76]  A. Golan,et al.  Ovarian hyperstimulation syndrome: an update review. , 1989 .

[77]  B. Fauser,et al.  Gonadotropin therapy for the treatment of anovulation and for ovarian hyperstimulation for IVF , 2002, Molecular and Cellular Endocrinology.

[78]  A. Yuzpe,et al.  An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome. , 2000, Fertility and sterility.

[79]  J. Grudzinskas,et al.  Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. , 1997, Human reproduction.

[80]  A. Brzezinski,et al.  Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. , 1988, American journal of obstetrics and gynecology.

[81]  S. Rozenberg,et al.  Is coasting effective for preventing ovarian hyperstimulation syndrome in patients receiving a gonadotropin-releasing hormone antagonist during an in vitro fertilization cycle? , 2001, Fertility and sterility.

[82]  E. Margalioth,et al.  The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. , 2001, Human reproduction.

[83]  D. Serr,et al.  Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. , 1987, Fertility and sterility.

[84]  L. Hunt,et al.  Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition? , 1993, British journal of obstetrics and gynaecology.

[85]  D. Imoedemhe,et al.  A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme. , 1991, Human reproduction.

[86]  A. Yajima,et al.  Laser vaporization of the ovarian surface in polycystic ovary disease results in reduced ovarian hyperstimulation and improved pregnancy rates. , 1995, American journal of obstetrics and gynecology.

[87]  N. Terakawa,et al.  Coasting May Reduce the Severity of the Ovarian Hyperstimulation Syndrome in Patients with Polycystic Ovary Syndrome , 2000, Gynecologic and Obstetric Investigation.

[88]  M. Aboulghar,et al.  Intra‐venous fluids preventing severe ovarian hyperstimulation syndrome , 2002 .

[89]  J. Itskovitz‐Eldor,et al.  Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. , 2000, Human reproduction.

[90]  D. Serr,et al.  Ovarian Hyperstimulation Syndrome Due To Exogenous Gonadotropin Administration , 1989, Acta obstetricia et gynecologica Scandinavica.

[91]  A. Golan,et al.  Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization. , 1988, Fertility and sterility.

[92]  R. Frydman,et al.  Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). , 2000, Fertility and sterility.

[93]  E. Shalev,et al.  Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study. , 1995, Human reproduction.

[94]  J. Emperaire,et al.  Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. , 1991, Human reproduction.

[95]  A. Ayhan,et al.  Ovarian hyperstimulation syndrome associated with spontaneous pregnancy. , 1996, Human reproduction.

[96]  L. Kahana,et al.  Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. , 1991, Fertility and sterility.

[97]  L. Veeck,et al.  Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. , 1997, Human reproduction.

[98]  M. Hussein,et al.  Limited ovarian stimulation (LOS), prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in polycystic ovarian disease. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[99]  S. Campbell,et al.  The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study. , 1992, Fertility and sterility.

[100]  Serge Rozenberg,et al.  Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. , 2002, Human reproduction update.

[101]  N. Santoro,et al.  Critical ovarian hyperstimulation syndrome in a coasted in-vitro fertilization patient. , 1998, Human reproduction.

[102]  T. Mukherjee,et al.  Severe ovarian hyperstimulation despite prophylactic albumin at the time of oocyte retrieval for in vitro fertilization and embryo transfer. , 1995, Fertility and sterility.

[103]  B. Rizk.  Pathophysiology of Ovarian Hyperstimulation Syndrome , 2001 .

[104]  J. Grudzinskas,et al.  Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. , 1999, Human reproduction.

[105]  R. Casper,et al.  Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. , 1990, The Journal of clinical endocrinology and metabolism.

[106]  G. Serour,et al.  Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome. , 1996, Fertility and sterility.

[107]  B. Dunphy,et al.  Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome. , 1994, Fertility and sterility.

[108]  M. Feinman,et al.  Eliminating the Risk of Life-Endangering Complications Following Overstimulation With Menotropin Fertility Agents: A Report on Women Undergoing In Vitro Fertilization and Embryo Transfer , 1993, Obstetrics and gynecology.

[109]  S. Franks,et al.  Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. , 1996, The Journal of clinical endocrinology and metabolism.

[110]  N. Amso,et al.  Prevention of ovarian hyperstimulation syndrome. , 1991 .

[111]  Z. Tuncer,et al.  Endocrinology: Ovarian hyperstimulation syndrome associated with spontaneous pregnancy , 1996 .

[112]  B. Fauser,et al.  Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. , 1995, Human reproduction.

[113]  M. Dhont,et al.  Prevention of severe ovarian hyperstimulation by coasting. , 1998, Fertility and sterility.

[114]  B. Urman,et al.  Management of overstimulated gonadotrophin cycles with a controlled drift period. , 1992, Human reproduction.

[115]  G. Serour,et al.  Complications of medically assisted conception in 3,500 cycles. , 1998, Fertility and sterility.

[116]  P. Devroey,et al.  Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization. , 1990, Human reproduction.

[117]  M. Goldenberg,et al.  Rescue of menotrophin cycles prone to develop ovarian hyperstimulation , 1987, British journal of obstetrics and gynaecology.

[118]  J G Grudzinskas,et al.  Prevention and treatment of ovarian hyperstimulation syndrome. , 2003, Best practice & research. Clinical obstetrics & gynaecology.

[119]  N. Amso,et al.  The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos. , 1990, Fertility and sterility.

[120]  V. Insler,et al.  Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. , 1994, Fertility and sterility.

[121]  E. Wallach,et al.  Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. , 1992, Fertility and sterility.

[122]  S. Rozenberg,et al.  Preventive attitude of physicians to avoid OHSS in IVF patients. , 2001, Human reproduction.

[123]  N. Dean,et al.  Elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome may not prevent the condition but reduces the live birth rate , 1996, Journal of Assisted Reproduction and Genetics.

[124]  B. Fauser,et al.  High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization. , 1998, Human reproduction.

[125]  C. Turan,et al.  Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[126]  J L Tullis,et al.  Albumin. 2. Guidelines for clinical use. , 1977, JAMA.

[127]  J. Gerris,et al.  Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome. , 1993, Human reproduction.

[128]  N. Panay,et al.  Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound for identification of high-risk patients. , 2001, Human reproduction.

[129]  V. Wiwanitkit,et al.  Ovarian hyperstimulation syndrome , 1991, The Lancet.

[130]  A. Leader,et al.  Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. , 1995, Human reproduction.

[131]  J. Antoine,et al.  Treatment of hyperstimulation during in-vitro fertilization. , 1990, Human reproduction.

[132]  Z. Rosenwaks,et al.  Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. , 2001, Fertility and sterility.

[133]  H. Zeyneloglu,et al.  Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study. , 1996, European journal of obstetrics, gynecology, and reproductive biology.

[134]  H. Yarali,et al.  The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. , 1993, Fertility and sterility.

[135]  N. Amso,et al.  Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. , 2002, Human reproduction.